115/04/26 09:30 - 12:30

-

實體+線上課程

時段	主題	講師	主持人
09:30~09:35	Opening Remarks
09:35~10:25	First 1 上市DPP4i 強力起跑，長期信賴	楊宗衡 院長 心安診所
10:25~11:15	First 1 雙價RSV 疫苗 高風險慢性病成人的即時保護 跨季心肺防護，獨特母嬰守護	曹玉婷 醫師 台大家醫	施君翰 監事 新北市醫師公會
11:15~11:30	Break Time
11:30~12:20	First 1 一針搞定 簡化慢性病成人肺炎鏈球菌預防 擴增血清型，提升防護	廖乙學 醫師 北醫家醫	施君翰 監事 新北市醫師公會
12:20~12:30	Panel discussion		ALL

1. 全球第二型糖尿病(T2DM)的罹病個數逐年增加；在台灣，T2DM及心血管疾病相關的共病症仍然是一大負擔。根據UKPDS研究的44年追蹤最新報告，及早在糖尿病診斷當下甚至是更早期的階段進行血糖控制，較晚期進行血糖控制可降低長期共病症或死亡的風險。亞洲族群之糖尿病患者因有較高碳水化合物飲食、胰島素功能較差等特性，Beta-cell 的功能相對也較西方國家族群低下；然而，在這樣的獨特族群中，將可從那些增進胰島素功能的糖尿病治療藥物得到更大的益處，如腸泌素或DPP4抑制劑。在病患罹病早期即進行合併治療策略，可以較早達到血糖控制外，Beta-cell 的功能也可以得到保護。亞洲病患使用DPP4i 或GLP-1RA可以較西方國家患者達到更好的血糖下降的效益
2. Respiratory syncytial virus (RSV) is an underrecognized cause of severe respiratory and cardiopulmonary morbidity in adults with chronic conditions. COPD, heart failure, diabetes, chronic kidney disease, and multimorbidity confer two- to eight-fold higher hospitalization risk, and over 90% of hospitalized RSV cases have at least one chronic disease. Acute cardiovascular events—including heart failure exacerbations and acute coronary syndromes—occur in roughly one-fifth of hospitalized patients.
Abrysvo, a bivalent RSV prefusion F vaccine, demonstrates strong real-world effectiveness against RSV-associated hospitalization and critical illness in adults ≥60 years, with sustained protection across two RSV seasons and consistent benefit in high-risk subgroups. Updated ACIP recommendations support universal vaccination for adults ≥75 years and risk-based vaccination for adults 60–74 years with chronic diseases, while 2026 GOLD guidelines extend vaccination to individuals ≥50 years with chronic heart or lung disease.
For Taiwan’s chronic disease population, Abrysvo represents an essential preventive intervention to mitigate RSV-related hospitalization, cardiopulmonary complications, and mortality.
3. Adults with chronic comorbidities experience substantially increased risk for pneumococcal disease, including invasive pneumococcal disease (IPD) and community-acquired pneumonia (CAP). Diabetes, COPD, chronic cardiac, hepatic, and renal diseases confer two- to six-fold increased IPD risk, with risk rising cumulatively with multimorbidity.
PCV20 provides expanded serotype coverage beyond PCV13, accounting for approximately 30% of additional adult IPD burden. Updated 2024 ACIP guidelines recommend PCV20 as the preferred pneumococcal vaccine for all adults ≥50 years and adults 19–49 years with risk conditions. Clinical trials demonstrate robust immunogenicity across all 20 serotypes and favorable safety in adults with stable chronic diseases.
The simplified single-dose regimen (“1 and done”) eliminates PPSV23 follow-on dosing, improving adherence within chronic disease management. Real-world evidence shows pneumococcal vaccination reduces severe disease and hospitalization risk, particularly in high-risk cardiometabolic and pulmonary populations. For Taiwan’s chronic disease adults, PCV20 serves as an evidence-based preventive strategy that integrates effectively into routine care.

晶華酒店/線上課程

-

-

中華民國糖尿病學會
中華民國醫師公會全國聯合會
台灣家庭醫學醫學會
社團法人中華民國糖尿病衛教學會
家醫計畫2.0時數DM 3 小時
《實際學分數以各醫學會實際通過為主，包含審查中之各醫學會學分》